Please : Actualité Please en direct - P5 | Bourse Reflex
Accueil > Tags > Please

  • Toutes les actualités en rapport avec « Please »

29/09 17:45 Please - Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

27/09 15:10 Please - 2016/17 publications

22/09 19:00 Please - GENTICEL PRESENTS FIRST HALF 2016 FINANCIAL RESULTS AND UPDATES ITS OPERATIONAL OUTLOOK

22/09 18:00 Please - Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension

22/09 08:30 Please - ABEO: Launch of the Initial Public Offering on Euronext Paris

21/09 17:55 Please - First-half 2016 results

16/09 18:00 Please - HALF-YEAR RESULTS TO 30 JUNE 2016

12/09 18:00 Please - Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

07/09 18:00 Please - Gilles Chamignon appointed Managing Director of Paref Gestion

06/09 16:35 Please - ABEO scores resounding success at Rio Olympic Games

27/07 17:35 Please - First-Half 2016 revenue

26/07 18:00 Please - First half 2016 results: downturn by 28% compared to first half 2015

25/07 13:00 Please - 2016 first half-year revenue

30/06 18:00 Please - Quantum Genomics Initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

28/06 18:00 Please - Quantum Genomics extends its collaboration agreement with its partner in animal health

15/06 19:30 Please - GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

15/06 09:00 Please - Initial Public Offering on Euronext - first step taken with filing of its Document de base

13/06 18:35 Please - GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

02/06 18:00 Please - Publication of the first issue of Quantum Genomics' shareholder newsletter - June, 2016

01/06 19:00 Please - GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001